Potentiation of androgen receptor transcriptional activity by inhibition of histone deacetylation - Rescue of transcriptionally compromised mutants

Journal of Endocrinology

Volumn 182, Issue 3, 2004, Pages 377-389

  Korkmaz, C G ^a   Fronsdal K ^a   Zhang, Y ^a   Lorenzo, P I ^a   Saatcioglu, Fahris ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BUTYRIC ACID; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DEPSIPEPTIDE; E1A PROTEIN; FR 901228; HISTONE; HISTONE ACETYLTRANSFERASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PROSTATE SPECIFIC ANTIGEN; TRICHOSTATIN A;

ACETYLATION; AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; DEACETYLATION; GENE ACTIVATION; GENE DELETION; GENETIC TRANSCRIPTION; HELA CELL; HUMAN; HUMAN CELL; MUTAGENESIS; MUTANT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPORTER GENE; TRANSCRIPTION INITIATION;

ACETYLATION; ANIMALS; BLOTTING, NORTHERN; BLOTTING, WESTERN; BUTYRATES; DEPRESSION, CHEMICAL; DEPSIPEPTIDES; HISTONE DEACETYLASES; HISTONES; HUMANS; HYDROXAMIC ACIDS; MALE; MUTATION; PEPTIDES, CYCLIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TRANSCRIPTION, GENETIC;

EID: 4644262388     PISSN: 00220795     EISSN: None     Source Type: Journal    
DOI: 10.1677/joe.0.1820377     Document Type: Article

References (51)

1. Aarnisalo P, Palvimo JJ & Janne OA 1998 CREB-binding protein in androgen receptor-mediated signaling. PNAS 95 2122-2127.
2. Bannister AJ & Kouzarides T 1996 The CBP co-activator is a histone acetyltransferase. Nature 384 641-643.
3. Chakravarti D, Ogryzko V, Kao HY, Nash A, Chen H, Nakatani Y & Evans RM 1999 A viral mechanism for inhibition of p300 and PCAF acetyltransferase activity. Cell 96 393-403.
4. Chan HM & La Thangue NB 2001 p300/CBP proteins: HATs for transcriptional bridges and scaffolds. Journal of Cell Science 114 2363-2373.
5. Conley BA, Egorin MJ, Tait N, Rosen DM, Sausville EA, Dover G, Fram RJ & Van Echo DA 1998 Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clinical Cancer Research 4 629-634.
6. Cress WD & Seto E 2000 Histone deacetylases, transcriptional control, and cancer. Journal of Cellular Physiology 184 1-16.
7. Deleu L, Shellard S, Alevizopoulos K, Amati B & Land H 2001 Recruitment of TRRAP required for oncogenic transformation by E1A. Oncogene 20 8270-8275.
8. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S & van Kuilenburg AB 2003 Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochemical Journal 370 737-749.
9. Doesburg P, Kuil CW, Berrevoets CA, Steketee K, Faber PW, Mulder E, Brinkimann AO & Trapman J 1997 Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 36 1052-1064.
10. Frønsdal K, Engedal N, Slagsvold T & Saatcioglu F 1998 CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1 Journal of Biological Chemistry 273 31853-31859 [erratum 1999 274 25188].
11. Frønsdal K, Engedal N & Saatcioglu F 2000 Efficient DNA-mediated gene transfer into prostate cancer cell line LNCaP. Prostate 43 111-117.
12. Fu M, Wang C, Reutens AT, Wang J, Angeletti RH, Siconolfi-Baez L, Ogryzko V, Avantaggiati ML & Pestell KG 2000 p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. Journal of Biological Chemistry 275 20853-20860.
13. Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D, Zhang X, Albanese C, Balk S, Chang C et al. 2003 Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Molecular and Cellular Biology 23 8563-8575.
14. Gaughan L, Logan IR, Cook S, Neal DE & Robson CN 2002 Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. Journal of Biological Chemistry 277 25904-25913.
15. Glass CK & Rosenfeld MG 2000 The coregulator exchange in transcriptional functions of nuclear receptors. Genes and Development 14 121-141.
16. Goodman RH & Smolik S 2000 CBP/p300 in cell growth, transformation, and development. Genes and Development 14 1553-1577.
17. Gregory CW, Hamil KG, Kim D, Hall SH, Pretlow TG, Mohler JL & French FS 1998 Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Research 58 5718-5724.
18. Gu W & Roeder RG 1997 Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 90 595-606.
19. He B & Wilson EM 2002 The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor. Molecular Genetics and Metabolism 75 293-298.
20. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA & Murphy GP 1983 LNCaP model of human prostatic carcinoma. Cancer Research 43 1809-1818.
21. Huang H, Reed CP, Zhang JS, Shridhar V, Wang L & Smith DI 1999 Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells. Cancer Research 59 2981-2988.
22. Hung HL, Lau J, Kim AY, Weiss MJ & Blobel GA 1999 CREB-binding protein acetylates hematopoietic transcription factor GATA-1 at functionally important sites. Molecular and Cellular Biology 19 3496-3505.
23. Ikonen T, Palvimo JJ & Janne OA 1997 Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. Journal of Biological Chemistry 272 29821-29828.
24. Jenster G, Spencer TE, Burcin MM, Tsai SY, Tsai MJ & O'Malley BW 1997 Steroid receptor induction of gene transcription: a two-step model. PNAS 94 7879-7884.
25. Korkmaz KS, Korkmaz CG, Ragnhildstveit E, Pretlow TG & Saatcioglu F 2000 An efficient procedure for cloning hormone-responsive genes from a specific tissue. DNA and Cell Biology 19 499-506.
26. Kramer OH, Gottlicher M & Heinzel T 2001 Histone deacetylase as a therapeutic target. Trends in Endocrinology and Metabolism 12 294-300.
27. Kwok RP, Lundblad JR, Chrivia JC, Richards JP, Bachinger HP, Brennan RG, Roberts SG, Green MR & Goodman RH 1994 Nuclear protein CBP is a coactivator for the transcription factor CREB. Nature 370 223-226.
28. Li Q, Imhof A, Collingwood TN, Urnov FD & Wolffe AP 1999 p300 stimulates transcription instigated by ligand-bound thyroid hormone receptor at a step subsequent to chromatin disruption. EMBO Journal 18 5634-5652.
29. Lindzey J, Kumar MV, Grossman M, Young C & Tindall DJ 1994 Molecular mechanisms of androgen action. Vitamins and Hormones 49 383-432.
30. List HJ, Smith CL, Rodriguez O, Danielsen M & Riegel AT 1999 Inhibition of histone deacetylation augments dihydrotestosterone induction of androgen receptor levels: an explanation for trichostatin A effects on androgen-induced chromatin remodeling and transcription of the mouse mammary tumor virus promoter. Experimental Cell Research 252 471-478.
31. Lundwall A & Lilja H 1987 Molecular cloning of human prostate specific antigen cDNA. FEBS Letters 214 317-322.
32. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P et al. 1995 The nuclear receptor superfamily: the second decade. Cell 83 835-839.
33. Marks PA, Richon VM & Rifkind RA 2000 Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. Journal of the National Cancer Institute 92 1210-1216.
34. McInerney EM, Tsai MJ, O'Malley BW & Katzenellenbogen BS 1996 Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator. PNAS 93 10069-10073.
35. McKenna NJ & O'Malley BW 2002 Minireview: nuclear receptor coactivators - an update. Endocrinology 143 2461-2465.
36. Newmark HL, Lupton JR & Young CW 1994 Butyrate as a differentiating agent: pharmacokinetics, analogues and current status. Cancer Letters 78 1-5.
37. Ogryzko VV, Schiltz RL, Russanova V, Howard BH & Nakatani Y 1996 The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87 953-959.
38. Perissi V, Dasen JS, Kurokawa R, Wang Z, Korzus E, Rose DW, Glass CK & Rosenfeld MG 1999 Factor-specific modulation of CREB-binding protein acetyltransferase activity. PNAS 96 3652-3657.
39. Quigley CA, De Bellis A, Marschke KB, el-Awady MK, Wilson EM & French FS 1995 Androgen receptor defects: historical, clinical, and molecular perspectives. Endocrine Reviews 16 271-321 [erratum 16 546].
40. Sadar MD & Gleave ME 2000 Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Research 60 5825-5831.
41. Sadowski I & Ptashne M 1989 A vector for expressing GAL4(1-147) fusions in mammalian cells. Nucleic Acids Research 17 7539.
42. Sakaguchi K, Herrera JE, Saito S, Miki T, Bustin M, Vassilev A, Anderson CW & Appella E 1998 DNA damage activates p53 through a phosphorylation-acetylation cascade. Genes and Development 12 2831-2841.
43. Samid D, Hudgins WR, Shack S, Liu L, Prasanna P & Myers CE 1997 Phenylacetate and phenylbutyrate as novel, nontoxic differentiation inducers. Advances in Experimental Medicine and Biology 400 501-505.
44. Shang Y, Myers M & Brown M 2002 Formation of the androgen receptor transcription complex. Molecular Cell 9 601-610.
45. Slagsvold T, Kraus I, Bentzen T, Palvimo J & Saatcioglu F 2000 Mutational analysis of the androgen receptor AF-2 (activation function 2) core domain reveals functional and mechanistic differences of conserved residues compared with other nuclear receptors. Molecular Endocrinology 14 1603-1617.
46. Thiagalingam S, Cheng KH, Lee HJ, Mineva N, Thiagalingam A & Ponte JF 2003 Histone deacetylases: unique players in shaping the epigenetic histone code. Annals of the New York Academy of Sciences 983 84-100.
47. Tsai MJ & O'Malley BW 1994 Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annual Review of Biochemistry 63 451-486.
48. Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y & Koizumi K 1976 A new antifungal antibiotic, trichostatin. Journal of Antibiotics (Tokyo) 29 1-6.
49. Xi Z, Klokk TI, Korkmaz K, Kurys P, Elbi C, Risberg B, Danielsen H, Loda M & Saatcioglu F 2004 Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Research 64 2365-2370.
50. Yoshida M, Kijima M, Akita M & Beppu T 1990 Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. Journal of Biological Chemistry 265 17174-17179.
51. Young CY, Andrews PE & Tindall DJ 1995 Expression and androgenic regulation of human prostate-specific kallikreins. Journal of Andrology 16 97-99.